semaglutide by novo nordisk Ozempic® (semaglutide) GLP-1 RA for Type 2 Diabetes Novo Nordisk relaunches diabetes pill

Revuz J, Clerici T

The question is no longer whether GLP-1 receptor agonists work

So that was always seen as a rationale why talking about what our evolutionary appropriate diets might be is irrelevant because we're talking about diseases that, you know, set in late life when evolution, that's probably simplistic

In comparison, research on Wegovy suggests it supports an average weight loss of around 16% after one year, 9% less than Zepbound

TRIUMPH-4 is a more targeted study enrolling 445 patients with both obesity and knee osteoarthritis

Frontal dysfunction underlies depression in mild cognitive impairment: A FDG-PET study